【摘要】 目的探讨急性髓细胞白血病(acute myelogenous leukaemia,AML)患者第1次缓解期自体外周血干细胞移植(autologous peripheral blood stem cell transplantation,APBSCT)的可行性和临床效果。方法1例诊断时高白细胞且伴有t(8;21),-Y异常的AML患者第1次完全缓解期(CR1),实施预处理方案为BU/CY2的APBSCT治疗,采集干细胞前进行包括大剂量阿糖胞苷在内的强化治疗以利于体内净化。结果移植相关毒性低,造血重建速度快,+12d血中性粒细胞绝对数(ANC)>0.5×109/L,PLT>20×109/L。患者已无事件存活32个月。结论年轻低中危非早幼粒白血病的AML患者CR1期大剂量阿糖胞苷强化治疗后进行APBSCT是合理的选择。更多还原

【Abstract】 Objective To assess the feasibility and efficacy of autologous peripheral blood stem cell transplantation(APBSCT) in patient with acute myelogenous leukaemia(AML) in first remission. Methods 1 AML patient with t(8;21) and high WBC count at diagnosis in first complete remission (CR) was treated with HD Ara-C intensification therapy as a method of in vivo purging before stem cell collection,then conditioned with a regimen consisting of busulfan and cyclophosphamide,followed by reinfusion of cryopreserved PBSC. Results The transplant-related morbidity was low and the hematologic recovery was quite rapid,the day to stable neutrophil count of 0.5×109/L and platelet count of 20×109/L after 12 days respectively. He has remained in effect-free survival for 32 months.Conclusion APBSCT is a reasonable option after HD Ara-C intensification therapy for younger AML patients with good or intermediate cytogenetics in first CR.更多还原